Form 4: Veracyte Chief Commercial Officer Sells Shares Under Pre-Arranged Trading Plan

Veracyte's Chief Commercial Officer, John Leite, sold 2,809 shares of common stock on June 4, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• John Leite, Veracyte's Chief Commercial Officer-CLIA, reported a sale of company common stock.
• The transaction occurred on June 4, 2025.
• A total of 2,809 shares were disposed of.
• The shares were sold at a weighted average price of $27.2018 per share, with individual sale prices ranging from $26.82 to $27.36.
• Following this transaction, Mr. Leite beneficially owns 94,540 shares of Veracyte common stock.
• The sale was executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Leite on December 6, 2024.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Commercial Officer, while reducing insider ownership, was conducted under a pre-established Rule 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new, non-public information, thus making the sentiment neutral.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, adopted on December 6, 2024, indicating a pre-scheduled transaction rather than a discretionary sale based on immediate market conditions or non-public information.

Negatives

• John Leite, Chief Commercial Officer-CLIA, reduced his direct ownership in Veracyte by selling 2,809 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted as a slight reduction in management's direct alignment with shareholder interests, though mitigated by the 10b5-1 plan.

Key Dates

Keywords

Veracyte, VCYT, Form 4, insider trading, stock sale, John Leite, Chief Commercial Officer, 10b5-1 plan, beneficial ownership